Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy - Mendell, JR; Al-Zaidy, SA; Lehman, KJ; McColly, M; Lowes, LP; Alfano, LN (JAMA Neurol, 2021)